NASDAQ · AUPH
Healthcare · Biotechnology
$15.69
Up+$0.32 (+2.04%)
Updated Oct 8, 2026, 12:32 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AUPH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AUPH closed at $15.69 after 20 trading sessions, down 3.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $15.77 | $15.82 | $15.47 | $15.69 | 699.17K |
| Oct 5, 2026 | $15.76 | $15.80 | $15.60 | $15.72 | 802.89K |
| Oct 2, 2026 | $16.06 | $16.06 | $15.74 | $15.83 | 813.43K |
| Oct 1, 2026 | $16.19 | $16.235 | $15.92 | $15.95 | 934.03K |
| Sep 30, 2026 | $16.43 | $16.4411 | $16.19 | $16.195 | 913.84K |
| Sep 29, 2026 | $16.39 | $16.48 | $16.16 | $16.42 | 734.7K |
| Sep 28, 2026 | $16.41 | $16.6178 | $16.24 | $16.52 | 626.25K |
| Sep 25, 2026 | $16.60 | $16.78 | $16.31 | $16.44 | 740.88K |
| Sep 24, 2026 | $16.35 | $16.66 | $16.28 | $16.595 | 809.43K |
| Sep 23, 2026 | $16.58 | $16.89 | $16.27 | $16.40 | 787.3K |
| Sep 22, 2026 | $16.72 | $16.805 | $16.55 | $16.67 | 885.01K |
| Sep 21, 2026 | $16.90 | $16.915 | $16.56 | $16.61 | 668.29K |
| Sep 18, 2026 | $16.93 | $17.03 | $16.80 | $16.90 | 1.2M |
| Sep 17, 2026 | $17.06 | $17.1599 | $16.75 | $16.96 | 850.19K |
| Sep 16, 2026 | $16.16 | $16.97 | $16.10 | $16.96 | 1.17M |
| Sep 15, 2026 | $16.35 | $16.35 | $15.98 | $16.13 | 942.04K |
| Sep 14, 2026 | $16.03 | $16.52 | $15.93 | $16.41 | 753.48K |
| Sep 11, 2026 | $16.28 | $16.35 | $16.055 | $16.10 | 745.44K |
| Sep 10, 2026 | $16.12 | $16.195 | $15.90 | $16.11 | 687.41K |
| Sep 9, 2026 | $15.97 | $16.32 | $15.85 | $16.25 | 723.3K |
The latest Smart Investors Daily articles mentioning AUPH.
Company
Market Activity
Research & News
AUPH research
Company profile and research snapshot.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Dec 3, 2025 | Leerink Partners | Market Perform | — |
| Nov 7, 2025 | Jefferies | Buy | — |
| Nov 5, 2025 | RBC Capital | Sector Perform | — |
| Aug 1, 2025 | RBC Capital | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 22, 2026
Aurinia Pharmaceuticals is now profitable, driven by LUPKYNIS, but faces a mature product with looming competition. Learn why AUPH stock is a hold.
Yahoo · Sep 16, 2026
On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]
Yahoo · Aug 28, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]
Benzinga · Aug 26, 2026
Revealing a significant insider sell on August 26, Stephen P Robertson, Chief Legal Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), as per the latest SEC filing. What Happened: A Form 4 filing with the U.S. Securities
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AUPH.
